17 Apr, 2017, 07:00 ET
PETACH TIKVA, Israel, April 17, 2017 /PRNewswire/ --
The Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC: OWCP), are pleased to announce that OWCP has been invited to present at the Monaco Growth Forums Spring, Edition, on April 25th - 26th at The Montepole Hotel in Monte Carlo, Monaco. During the event, management will introduce OWC Pharmaceutical's approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP's CSO& CTO will also be a Keynote Speaker at MGF's Cocktail Reception on Wednesday, April 26th. The keynote topic will be "Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.
Mr. Mordechai Bignitz, Chairman and CEO commented, "We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC's unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.
"Andreea Porcelli, CEO and Founder of Monaco Growth Forums commented, "We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area."
For more information or to RSVP for the MGF Spring Conference event and one-on-one investor meetings with OWC Pharmaceutical Research Corp., contact Sevinc Bermek, Events Coordinator: [email protected] or visit https://monacogrowthforums.com/ .
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information visit: http://www.owcpharma.com/
About Monaco Growth Forums by Andreea Porcelli Ltd.
Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, MGF Founder, and President has more than 20 years experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations-all of whom are also exclusively invited to match MFG's highly selective criteria. http://www.monacogrowthforums.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.
Mordechai Bignitz Chairman and CEO
Email: [email protected]
SOURCE OWC Pharmaceutical Research Corp.
Share this article